CosmoFarm Subsidiary Posts Record $15M Q2 Revenue, $60M+ Annualized Run-Rate
COSM is trading near its 52-week low of $0.183 (9.6% above the low) on elevated volume (2.6× avg).
Summary
Cosmos Health's subsidiary, CosmoFarm, reported record Q2 2026 revenue exceeding $15 million, translating to an annualized run-rate over $60 million. This strong performance, which includes adding over 80 pharmacies and investing in AI automation and facility expansion, follows recent SEC filings (10-K, 10-Q) that disclosed going concern warnings, widened losses, and increased cash burn for the parent company. The annualized revenue for CosmoFarm is nearly equivalent to Cosmos Health's total reported revenue for fiscal year 2025, highlighting its critical contribution. This positive operational update provides a counterpoint to the company's financial headwinds and potential dilution from recent ATM offerings.
At the time of this announcement, COSM was trading at $0.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.5M. The 52-week trading range was $0.18 to $1.32. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.